Stock THTX THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-07-17 EDT 		5-day change 1st Jan Change
1.535 USD -2.69% Intraday chart for Theratechnologies Inc. +2.33% -5.25%
07-10 Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 CI
07-10 Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Theratechnologies: Fiscal Q2 Earnings Snapshot
AQ
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
AQ
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
AQ
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
AQ
Theratechnologies Reports on its Annual Meeting of Shareholders
AQ
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
AQ
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
AQ
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
Theratechnologies: Fiscal Q1 Earnings Snapshot
AQ
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
AQ
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
AQ
Theratechnologies Appoints Elina Tea to its Board of Directors
AQ
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
AQ
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
AQ
Theratechnologies Announces Update on its Preclinical Oncology Research Program
AQ
Theratechnologies Appoints Jordan Zwick to its Board of Directors
AQ
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
AQ
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
AQ
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
AQ
Theratechnologies: Fiscal Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TH Stock
  4. THTX Stock
  5. News Theratechnologies Inc.
  6. Press Releases